Astellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low - Time to Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares reached a new 52-week low during trading on Thursday . The company traded as low as $8.55 and last traded at $9.01, with a volume of 790563 shares traded. The stock had previously closed at $8.99.

Astellas Pharma Stock Up 2.8 %

The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market cap of $16.52 billion, a P/E ratio of -41.50 and a beta of 0.31. The firm's 50-day simple moving average is $9.62 and its 200 day simple moving average is $10.17.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, research analysts forecast that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.